GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Bio Medica Corp (OTCPK:ABMC) » Definitions » ROE %

American Bio Medica (American Bio Medica) ROE % : Negative Equity% (As of Mar. 2023)


View and export this data going back to . Start your Free Trial

What is American Bio Medica ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. American Bio Medica's annualized net income for the quarter that ended in Mar. 2023 was $7.52 Mil. American Bio Medica's average Total Stockholders Equity over the quarter that ended in Mar. 2023 was $-1.40 Mil. Therefore, American Bio Medica's annualized ROE % for the quarter that ended in Mar. 2023 was Negative Equity%.

The historical rank and industry rank for American Bio Medica's ROE % or its related term are showing as below:

ABMC's ROE % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -6.965
* Ranked among companies with meaningful ROE % only.

American Bio Medica ROE % Historical Data

The historical data trend for American Bio Medica's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Bio Medica ROE % Chart

American Bio Medica Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -431.03 - - - -

American Bio Medica Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - Negative Equity

Competitive Comparison of American Bio Medica's ROE %

For the Diagnostics & Research subindustry, American Bio Medica's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Bio Medica's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Bio Medica's ROE % distribution charts can be found below:

* The bar in red indicates where American Bio Medica's ROE % falls into.



American Bio Medica ROE % Calculation

American Bio Medica's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-1.41/( (-0.944+-2.339)/ 2 )
=-1.41/-1.6415
=N/A %

American Bio Medica's annualized ROE % for the quarter that ended in Mar. 2023 is calculated as

ROE %=Net Income (Q: Mar. 2023 )/( (Total Stockholders Equity (Q: Dec. 2022 )+Total Stockholders Equity (Q: Mar. 2023 ))/ count )
=7.524/( (-2.339+-0.458)/ 2 )
=7.524/-1.3985
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


American Bio Medica  (OTCPK:ABMC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=7.524/-1.3985
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(7.524 / 0.656)*(0.656 / 0.964)*(0.964 / -1.3985)
=Net Margin %*Asset Turnover*Equity Multiplier
=1146.95 %*0.6805*N/A
=ROA %*Equity Multiplier
=780.5 %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=7.524/-1.3985
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (7.524 / 7.524) * (7.524 / -0.848) * (-0.848 / 0.656) * (0.656 / 0.964) * (0.964 / -1.3985)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * -8.8726 * -129.27 % * 0.6805 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


American Bio Medica ROE % Related Terms

Thank you for viewing the detailed overview of American Bio Medica's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


American Bio Medica (American Bio Medica) Business Description

Traded in Other Exchanges
N/A
Address
122 Smith Road, Kinderhook, New York, NY, USA, 12106
American Bio Medica Corp is a us-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.
Executives
Stuart Steinberg 10 percent owner 85 BELLEVUE AVENUE, RYE NY 10580
John J Moroney 10 percent owner 118 PEGASUS DR., JUPITER FL 33477
Chaim Davis director 2601 PINE TREE DRIVE, MIAMI BEACH FL 33140
Peter Jerome director 7 RIDGECREST AVE, LATHAM NY 12110
Diane Generous director 122 SMITH ROAD, KINDERHOOK NY 12106
Melissa A Waterhouse officer: EVP, CCO, CORP SEC AMERICAN BIO MEDICA CORPORATION, 122 SMITH ROAD, KINDERHOOK NY 12106
Mp Biomedicals Llc 10 percent owner 3 HUTTON CENTRE DRIVE, SUITE 100, SANTA ANA CA 92707
Douglas Casterlin officer: Executive Vice President C/O MELISSA A. WATERHOUSE/ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Jean Neff director C/O ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Stefan Parker officer: Chief Financial Officer 122 SMITH ROAD, KINDERHOOK NY 12106
Carl A Florio director C/O HUDSON RIVER BANK & TRUST CO, PO BOX 76, HUDSON NY 12534
Stan Cipkowski director 300 S LAKE DR, STE 340, FISHKILL NY 12553
Anthony G Costantino director 122 SMITH ROAD, KINDERHOOK NY 12106
Edmund M Jaskiewicz director, officer: President
Richard Koskey director C/O ABMC 122 SMITH ROAD, 122 SMITH ROAD, KINDERHOOK NY 12106

American Bio Medica (American Bio Medica) Headlines